Stanton will serve on DiaMedica’s Kidney Scientific Advisory Board.
MINNEAPOLIS, Oct. 31, 2017 (GLOBE NEWSWIRE) -- DiaMedica (the “DiaMedica”) (TSX Venture:DMA) (OTCQB:DMCAF) is pleased to announce that Dr. Robert Stanton, Chief of the Kidney and Hypertension Section and a Principal Investigator of Vascular Cell Biology at Joslin Diabetes Center, a Harvard Medical School affiliate, will serve on DiaMedica’s Kidney Scientific Advisory Board.
“Dr. Stanton has an extensive and successful history of conducting research into the causes, complications, and treatment options of kidney disease. In September of this year, he published an important review paper titled “The Kallikrein-Kinin System in Diabetic Kidney Disease1,” stated Mr. Rick Pauls, President and CEO of DiaMedica. “Dr. Stanton will be an excellent advisor for our upcoming clinical studies in patients with chronic kidney disease.”
Dr. Stanton commented, “I look forward to assisting the advancement of therapies for treating patients with chronic kidney disease.”
About Joslin Diabetes Center
Joslin Diabetes Center, affiliated with Harvard Medical School, is the world’s preeminent diabetes research and clinical care organization. Joslin, through its cutting-edge research and innovative approaches to clinical care and education, is dedicated both to helping people with diabetes live long, healthy lives and to finding a cure.
About Dr. Stanton
Robert C. Stanton, M.D. is the Chief of the Kidney and Hypertension Section at Joslin Diabetes Center and is a Principal Investigator in the Section on Vascular Cell Biology. Dr. Stanton is an Associate Professor of Medicine at Harvard Medical School where he is involved with teaching at all levels. Dr. Stanton has lectured all over the world. He has received three Honorary Professorships from Universities in China. Dr. Stanton is an author of many original articles and chapters.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica’s shares are listed on the TSX Venture Exchange under the trading symbol “DMA” and on the OTCQB under the trading symbol “DMCAF”. For more information, please visit www.diamedica.com. Follow us on social media – Twitter, LinkedIn.
Contact:
Paul Papi
Vice President of Business Development
DiaMedica Therapeutics Inc.
Phone: (617) 899-5941
info@diamedica.com
FORWARD-LOOKING STATEMENTS
The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words “may”, “will”, “anticipate”, “believe”, “estimate”, “expect”, “intend” and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the DiaMedica’s filings with the Canadian securities regulators, all of which are available on SEDAR (www.sedar.com). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise, or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.
1Curr Opin Nephrol Hypertens 2017, 26:351–357.
